title: Clinical and microbiological efficacy of prulifloxacin for the treatment of chronic bacterial prostatitis due to Chlamydia trachomatis infection: results from a prospective, randomized and open-label study.
abstract: The purpose of this study was to compare the efficacy of a 14-day course of prulifloxacin 600 mg with standard antibiotic therapy for the treatment of chronic prostatitis due to Chlamydia trachomatis (Ct) infection. All patients with clinical and instrumental diagnosis of bacterial chronic prostatitis (CP) due to Ct infection were enrolled. After randomization, all patients were administered oral prulifloxacin 600 mg once daily for 14 days or doxycycline 100 mg orally twice daily for 21 days. At enrollment and 30 days after beginning treatment, all patients underwent microbiological cultures for uropathogens bacteria and yeasts, DNA extraction and mucosal IgA evaluation for Ct diagnosis, seminal plasma IL-8 evaluation and serum IgA and IgG anti-Ct analysis. The National Institutes of Health - Chronic Prostatitis Symptom Index (NIH-CPSI) was given to each patient. A total of 109 patients received prulifloxacin and 102 received standard therapy. Prulifloxacin had clinical efficacy rates equivalent to standard therapy (82.5% vs. 79.9%) (P = 0.08) and showed superior microbiological efficacy rates compared to standard therapy, in terms of decreasing mucosal IgA (P < 0.001) and IL-8 levels (P < 0.001). Prulifloxacin was also equivalent to standard therapy for clinical success, as demonstrated by a decrease in the number of patients affected by CP due to Ct infection.
authors.affiliation: Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy. ktommy@libero.it
authors.forename: Tommaso
authors.initials: T
authors.lastname: Cai
authors.forename: S
authors.initials: S
authors.lastname: Mazzoli
authors.forename: P
authors.initials: P
authors.lastname: Addonisio
authors.forename: V
authors.initials: V
authors.lastname: Boddi
authors.forename: P
authors.initials: P
authors.lastname: Geppetti
authors.forename: R
authors.initials: R
authors.lastname: Bartoletti
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002690:Chlamydia Infections / Q000188:drug therapy* / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000187:drug effects / Q000302:isolation & purification; D004148:Dioxolanes / Q000627:therapeutic use*; D004318:Doxycycline / Q000627:therapeutic use; D024841:Fluoroquinolones / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007070:Immunoglobulin A / Q000187:drug effects / Q000378:metabolism; D016209:Interleukin-8 / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011446:Prospective Studies; D011472:Prostatitis / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D004148:Dioxolanes; D024841:Fluoroquinolones; D007070:Immunoglobulin A; D016209:Interleukin-8; D010879:Piperazines; C074191:prulifloxacin; D004318:Doxycycline